MOC Stock Overview
Molecure S.A., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of neoplastic and inflammatory diseases in Poland.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Molecure S.A. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | zł17.12 |
52 Week High | zł26.25 |
52 Week Low | zł15.64 |
Beta | 2.21 |
1 Month Change | -13.88% |
3 Month Change | -8.74% |
1 Year Change | -19.81% |
3 Year Change | -68.18% |
5 Year Change | -12.65% |
Change since IPO | -40.97% |
Recent News & Updates
Recent updates
We're Keeping An Eye On Molecure's (WSE:MOC) Cash Burn Rate
Dec 01Is Molecure (WSE:MOC) In A Good Position To Invest In Growth?
Jul 07Companies Like Molecure (WSE:MOC) Are In A Position To Invest In Growth
Mar 10Companies Like Molecure (WSE:MOC) Are In A Position To Invest In Growth
Aug 16OncoArendi Therapeutics' (WSE:OAT) Earnings Are Weaker Than They Seem
Nov 04Is OncoArendi Therapeutics S.A.'s (WSE:OAT) Shareholder Ownership Skewed Towards Insiders?
Feb 24Will OncoArendi Therapeutics (WSE:OAT) Spend Its Cash Wisely?
Jan 02Shareholder Returns
MOC | PL Pharmaceuticals | PL Market | |
---|---|---|---|
7D | -3.3% | -2.5% | 2.1% |
1Y | -19.8% | -2.9% | 35.7% |
Return vs Industry: MOC underperformed the Polish Pharmaceuticals industry which returned -0.5% over the past year.
Return vs Market: MOC underperformed the Polish Market which returned 34.3% over the past year.
Price Volatility
MOC volatility | |
---|---|
MOC Average Weekly Movement | 4.1% |
Pharmaceuticals Industry Average Movement | 5.2% |
Market Average Movement | 5.0% |
10% most volatile stocks in PL Market | 9.6% |
10% least volatile stocks in PL Market | 3.3% |
Stable Share Price: MOC has not had significant price volatility in the past 3 months.
Volatility Over Time: MOC's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2012 | 109 | Marcin Szumowski | https://molecure.com |
Molecure S.A., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of neoplastic and inflammatory diseases in Poland. The company is involved in the development of OATD-01, a chitotriosidase/AMCASE inhibitor that has completed phase I clinical trial for the treatment of sarcoidosis, as well as in preclinical stage to treat idiopathic pulmonary fibrosis and NASH. It also develops OATD-02, an arginase 1 and arginase 2, which is in Phase I clinical trial for the treatment of cancer; USP7, USP21, and YKL-40 for the treatment of cancer; and Deubiquitinase program.
Molecure S.A. Fundamentals Summary
MOC fundamental statistics | |
---|---|
Market cap | zł288.23m |
Earnings (TTM) | -zł17.41m |
Revenue (TTM) | zł1.38m |
209.5x
P/S Ratio-16.6x
P/E RatioIs MOC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
MOC income statement (TTM) | |
---|---|
Revenue | zł1.38m |
Cost of Revenue | zł1.80m |
Gross Profit | -zł424.51k |
Other Expenses | zł16.99m |
Earnings | -zł17.41m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
Mar 29, 2024
Earnings per share (EPS) | -1.03 |
Gross Margin | -30.86% |
Net Profit Margin | -1,265.69% |
Debt/Equity Ratio | 0% |
How did MOC perform over the long term?
See historical performance and comparison